Precipio (NASDAQ:PRPO) Upgraded at Wall Street Zen

Precipio (NASDAQ:PRPO) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Precipio Stock Up 4.3%

PRPO stock opened at $23.39 on Friday. Precipio has a one year low of $3.90 and a one year high of $28.50. The firm has a market cap of $40.98 million, a PE ratio of -28.52 and a beta of 1.20. The firm’s 50 day moving average price is $23.60 and its 200-day moving average price is $20.42. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. The business had revenue of $6.77 million during the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.

Institutional Investors Weigh In On Precipio

Institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP purchased a new stake in shares of Precipio in the 3rd quarter valued at $194,000. Renaissance Technologies LLC grew its position in Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares in the last quarter. Evernest Financial Advisors LLC purchased a new stake in Precipio during the third quarter worth about $374,000. Geode Capital Management LLC lifted its position in shares of Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares in the last quarter. Finally, Topline Capital Management LLC purchased a new position in shares of Precipio in the third quarter valued at approximately $1,158,000. 10.45% of the stock is owned by institutional investors and hedge funds.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.